Evidence map›Paper›PMID 16504291›Full record

ArticleLeukemia research2006

The NPM-RAR fusion protein associated with the t(5;17) variant of APL does not interact with PML.

Elizabeth A Rush, Kimberly W Schlesinger, Simon C Watkins, Robert L Redner

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Elizabeth A RushDepartment of Medicine, University of Pittsburgh Medical Center and the University of Pittsburgh Cancer Institute, USA.
Kimberly W Schlesinger
Simon C Watkins
Robert L Redner
UPMC Hillman Cancer Center · US

Funding

NOVEL TRANSLOCATION PRODUCT IN APLR29CA067346 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REDNER, ROBERT L · 1995 to 1999
–
NCI NIH HHS R29 CA67346
6 · The paper itself

Abstract

The PML protein localizes to regions of the nucleus known as nuclear bodies or PODs. However, in t(15;17) Acute Promyelocytic Leukemia (APL) blasts, PML is found in a micro-punctate pattern. In order to test the hypothesis that delocalization of PML from PODs is necessary for APL, we investigated the interaction of the t(5;17) APL fusion protein NPM-RAR with PML. NPM-RAR localizes diffusely throughout the nucleoplasm. NPM-RAR does not alter the localization of PML in transfected HeLa cells, and does not associate with PML in vitro. These studies suggest that NPM-RAR does not interact with PML.

Indexed as

AnimalsChlorocebus aethiopsChromosomes, Human, Pair 17Chromosomes, Human, Pair 5COS CellsHeLa CellsHumansLeukemia, Promyelocytic, AcuteNeoplasm ProteinsNuclear ProteinsOncogene Proteins, FusionPolymerase Chain ReactionPromyelocytic Leukemia ProteinProtein BindingSensitivity and SpecificityTranscription FactorsNeoplasm ProteinsNPM-RARalpha protein, humanNuclear ProteinsOncogene Proteins, FusionPML protein, humanPromyelocytic Leukemia ProteinTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID16504291
OpenAlexW1966442422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.